Replies to post #21095 on Ayala Pharmaceuticals Inc (ADXS)

[JB-22]

Then maybe ADXS should have added in lieu of upfront cash we decided to negotiate terms at a later date with regards to revenue sharing if data progresses accordingly. This isn't a preclinical. Although many preclinicals are receiving upfront payments. The PR is vague at best